Three cardiovascular trials dropped at the American College of Cardiology meeting this weekend. One matters immediately.
The FlowTriever system — think vacuum cleaner meets heart catheter — showed a 26% reduction in death or clinical deterioration when treating massive pulmonary embolisms. That’s the blood clot that kills you fast, blocking major arteries to your lungs.
The numbers: 518 patients across 68 hospitals. Half got the catheter treatment plus standard blood thinners. Half got blood thinners alone. The catheter group had significantly better outcomes at 30 days.
This isn’t incremental improvement. Massive PE has a 15-30% mortality rate. Finding something that moves the needle this much is rare.
The device works mechanically — it physically removes clots rather than waiting for drugs to dissolve them. Speed matters when your lungs can’t get blood flow.
Two other trials made headlines but won’t change practice immediately. The Impella heart pump showed marginal benefits during high-risk heart procedures. And researchers confirmed that a zero calcium score on heart scans means very low cardiovascular risk for the next decade — useful for insurance purposes, less so for clinical decisions.
But the clot-buster represents something bigger: mechanical solutions for time-critical cardiovascular events. We’re seeing this across emergency medicine — devices that bypass the body’s slower biological processes.
The Protocol says: This will become standard care within 18 months. The mortality benefit is too clear to ignore, and the procedure fits existing catheter lab infrastructure.
Emergency medicine just got more aggressive about keeping people alive past their expiration date.
Data presented at the American College of Cardiology annual scientific meeting in New Orleans.